| Results for the year | Results for the year 2.1 Net sales and rebates Gross-to-net sales reconciliation DKK million 2024 2023 2022 Gross sales 680,563 608,645 455,692 US Managed Care and Medicare (238,946) (223,191) (161,123) US wholesaler charge-backs (64,437) (74,435) (56,443) US Medicaid rebates (32,919) (31,821) (24,667) Other US discounts and sales returns (30,737) (28,481) (18,300) US rebates, discounts and sales returns (367,039) (357,928) (260,533) Non-US rebates, discounts and sales returns (23,121) (18,456) (18,205) Total gross-to-net sales adjustments (390,160) (376,384) (278,738) Net sales 290,403 232,261 176,954 Provisions for sales rebates DKK million 2024 2023 2022 At the beginning of the year 99,878 69,499 50,822 Additional provisions, including increases to existing provisions 318,812 285,266 206,354 Amount paid during the year (299,334) (250,316) (189,580) Adjustments regarding prior years, including unused amounts reversed during the year (6,452) (2,364) (1,141) Effect of exchange rate adjustment 5,612 (2,207) 3,044 At the end of the year 118,516 99,878 69,499 Sales discounts and sales rebates are predominantly issued in the US. As such, total US rebates, discounts and sales returns amounts to DKK (367,039) million, corresponding to 69% of gross sales in the US (74% in 2023 and 75% in 2022). Provisions for sales rebates include US Managed Care, Medicare, Medicaid, 340B Pricing mechanisms in the US market In the US, sales rebates are paid in connection with public healthcare insurance programmes, including Medicare and Medicaid, as well as rebates to pharmacy benefit managers (PBMs) and managed healthcare plans. Key customers in the US include private payers, PBMs and government payers. PBMs and managed healthcare plans play a role in negotiating price concessions with drug manufacturers for both the commercial and government channels, and determine which drugs are covered on their formularies (or 'preferred drug lists'). US Managed Care and Medicare For Managed Care and Medicare, rebates are offered to a number of PBMs and managed healthcare plans. These rebate programmes allow the customer to receive a rebate after attaining certain performance parameters relating to formulary status or pre-established market share thresholds. Rebate provisions are estimated according to the specific terms in each agreement, historical experience, anticipated channel mix, growth rates and market share information. Novo Nordisk adjusts the provision periodically to reflect actual sales performance. Managed Care and Medicare rebates are generally settled around 100 days from the transaction date. US wholesaler charge-backs Wholesaler charge-backs relate to contractual arrangements between Novo Nordisk and indirect customers in the US whereby products are sold at contract prices lower than the list price originally charged to wholesalers. Chargeback provisions are estimated using a combination of factors such as historical experience, current wholesaler inventory levels, contract terms and the value of claims received but not yet processed. Wholesaler charge-backs are generally settled within 30 days after receipt of claim. In January 2021, Novo Nordisk changed its policy in the US related to the 340B Drug Pricing Program, whereby Novo Nordisk no longer provides 340B statutory discounts to certain pharmacies that contract with covered entities participating in the 340B Drug Pricing Program. Novo Nordisk has recognised revenue related to the 340B Drug Pricing Program to the extent that it is highly probable that its inclusion will not result in a significant revenue reversal in the future. Management’s assessment considers interpretations of applicable laws, legal and administrative rulings, as well as attrition and experience from historical claims. During 2024, additional provisions for 340B statutory discounts of net USD 0.8 billion were recognised. As of 31 December 2024, provisions for sales rebates comprise a provision for 340B statutory discounts of Refer to note 3.5 for a more elaborate description of the ongoing litigation related to the 340B Drug Pricing Program. US Medicaid rebates Medicaid is a government insurance programme. Medicaid rebates have been estimated using a combination of historical experience, product and population growth, price changes and the impact of contracting strategies. The calculation also involves interpretation of relevant regulations that are subject to changes in interpretative guidance from government authorities. Novo Nordisk adjusts the provision periodically to reflect actual sales performance. Medicaid rebates Other US and non-US discounts and sales returns Other discounts are provided to distributors, wholesalers, hospitals, pharmacies, etc. Further, discounts are provided to patients through different programmes.They are usually linked to sales volume or provided as cash discounts. Discounts are calculated based on historical data and recorded as a reduction in gross sales at the time the related sales are recorded. Sales returns relate to damaged or expired products. Other net sales disclosures In 2024, Novo Nordisk had 3 major wholesalers distributing products in the US, representing 23%, 17% and 17% respectively of global net sales (22%, 17% and 15% in 2023 and 19%, 14% and 13% in 2022). Sales to these 3 wholesalers are within both Diabetes and Obesity care and Rare disease. Net sales to be recognised from existing customer contracts containing fixed or minimum sales volumes, with an original term greater than 12 months, are expected to be DKK 3,753 million within 12 months (DKK 3,166 million in 2023) and DKK 5,822 million thereafter (DKK 443 million). KEY ACCOUNTING ESTIMATES OF SALES DEDUCTIONS AND Sales deductions are estimated and provided for at the time the related sales are recorded. These estimates of unsettled rebate, discount and product return obligations is considered a key accounting estimate as not all conditions are known at the time of sale, for example total sales volume to a given customer. The estimates are based on analyses of existing contractual obligations and historical experience. Provisions are calculated on the basis of a percentage of sales for each product as defined by the contracts with the various customer groups. Provisions for sales rebates are adjusted to actual amounts as rebates, discounts and returns are processed. Revenue related to the 340B Drug Pricing Program can only be recognised to the extent that it is highly probable that a significant reversal of the recognised revenue will not occur. Novo Nordisk considers the provisions established for sales rebates to be reasonable and appropriate based on the information currently available. However, the actual amount of rebates and discounts may differ from the amounts estimated by Management as more detailed information becomes available. ACCOUNTING POLICIES Revenue from sale of goods is recognised when Novo Nordisk has transferred In some markets, Novo Nordisk sells products on a sale-or-return basis. Where there Unsettled rebates are recognised as provisions when the timing or amount is uncertain (note 3.5). Where absolute amounts are known, the rebates are recognised as other liabilities. Wholesaler charge-backs that are absolute are netted against trade receivable balances. The impact of foreign currency hedging in the income statement is recognised as 2.2 Segment information Operating segments – Key figures Diabetes and Obesity care Rare disease Total DKK million 2024 2023 2022 2024 2023 2022 2024 2023 2022 Net sales 271,764 215,098 156,412 18,639 17,163 20,542 290,403 232,261 176,954 Cost of goods sold (37,760) (30,483) (23,405) (6,762) (5,282) (5,043) (44,522) (35,765) (28,448) Sales and distribution costs (57,840) (52,477) (42,392) (4,261) (4,266) (3,825) (62,101) (56,743) (46,217) Research and development costs (41,490) (28,073) (20,157) (6,572) (4,370) (3,890) (48,062) (32,443) (24,047) Administrative costs (4,881) (4,435) (3,955) (395) (420) (512) (5,276) (4,855) (4,467) Other operating income and expenses (2,074) (7) 892 (29) 126 142 (2,103) 119 1,034 Segment operating profit 127,719 99,623 67,395 620 2,951 7,414 128,339 102,574 74,809 Operating margin 47.0 % 46.3 % 43.1 % 3.3 % 17.2 % 36.1 % 44.2 % 44.2 % 42.3 % Depreciation and amortisation expenses (7,104) (6,042) (5,421) (1,441) (1,247) (1,132) (8,545) (7,289) (6,553) Impairment losses and reversals (9,262) (2,153) (280) (1,300) 29 (529) (10,562) (2,124) (809) Total depreciation, amortisation, impairment losses and reversals (16,366) (8,195) (5,701) (2,741) (1,218) (1,661) (19,107) (9,413) (7,362) Operating segments Novo Nordisk operates in two segments based on therapies: Diabetes and Obesity care and Rare disease, representing the entirety of the Group's operations. The activities of the segments include research, development, manufacturing and marketing of products within the following areas: • Diabetes and Obesity care: diabetes, obesity, cardiovascular and emerging therapy areas • Rare disease: rare blood disorders, rare endocrine disorders and hormone replacement therapy. Segment performance is evaluated on the basis of operating profit, consistent with the Consolidated financial statements. Financial income and expenses and income taxes are managed at Group level and are not allocated to segments. There are no sales or other transactions between the segments. Costs have generally been split between segments according to a specific allocation. Certain corporate overhead costs are allocated between segments based on overall allocation keys. Other operating income and expenses have been allocated to the two segments based on the same principle. ACCOUNTING POLICIES Operating segments are reported in a manner consistent with the internal reporting provided to Executive Management and the Board of Directors. We consider Executive Management to be the operating decision-making body. Geographical areas In 2024, Novo Nordisk operated in two main commercial units: • International Operations • EMEA: Europe, the Middle East and Africa. • Region China: Mainland China, Hong Kong and Taiwan. • Rest of World: All other countries except for North America. • North America Operations (the US and Canada). In 2024, the US contributed 10% or more of total net sales. In 2023, the US also contributed 10% or more of total net sales. The country of domicile is Denmark, which is part of EMEA. Denmark is immaterial to Novo Nordisk's activities in terms of sales as 99.2% of total net sales are realised outside Denmark (99.2 % in 2023). Sales are attributed to geographical areas according to the location of the customer. Total property, plant and equipment and intangible assets amounts to DKK 273,578 million (DKK 151,367 million in 2023), of which DKK 177,471 million is located in Denmark (DKK 82,274 million in 2023) and DKK 57,141 million is located in the US (DKK 46,609 million in 2023). Net sales – Segments and geographical areas Total International Operations Total North America Operations Total Novo Nordisk Total IO EMEA Region China Rest of World Total NAO US DKK million 2024 2023 2022 2024 2023 2022 2024 2023 2022 2024 2023 2022 2024 2023 2022 2024 2023 2022 2024 2023 2022 Diabetes and Obesity care segment: Ozempic ® 29,055 26,378 17,369 16,001 14,327 10,417 5,762 4,821 2,196 7,292 7,230 4,756 91,287 69,340 42,381 84,201 63,010 38,750 120,342 95,718 59,750 Rybelsus ® 12,231 7,389 3,155 7,136 4,232 1,714 511 131 63 4,584 3,026 1,378 11,070 11,361 8,144 10,795 11,060 8,011 23,301 18,750 11,299 Victoza ® 3,686 4,850 5,672 1,422 2,166 2,724 975 1,256 1,478 1,289 1,428 1,470 1,796 3,814 6,650 1,699 3,613 6,406 5,482 8,664 12,322 Total GLP-1 44,972 38,617 26,196 24,559 20,725 14,855 7,248 6,208 3,737 13,165 11,684 7,604 104,153 84,515 57,175 96,695 77,683 53,167 149,125 123,132 83,371 Long-acting insulin 12,884 11,339 11,403 7,686 7,103 7,157 2,696 1,649 1,636 2,502 2,587 2,610 6,211 3,566 5,338 5,538 2,931 4,685 19,095 14,905 16,741 • of which Awigli ® 15 — — 9 — — 6 — — — — — 4 — — — — — 19 — — • of which Tresiba ® 6,494 5,864 6,092 3,876 3,435 3,485 978 848 1,050 1,640 1,581 1,557 3,411 1,888 3,261 2,806 1,333 2,723 9,905 7,752 9,353 • of which Xultophy ® 4,217 2,887 2,400 2,185 1,831 1,716 1,414 409 45 618 647 639 286 332 409 281 325 399 4,503 3,219 2,809 • of which Levemir ® 2,158 2,588 2,911 1,616 1,837 1,956 298 392 541 244 359 414 2,510 1,346 1,668 2,451 1,273 1,563 4,668 3,934 4,579 Premix insulin 10,143 9,342 10,023 2,637 2,570 2,622 4,784 4,441 4,912 2,722 2,331 2,489 646 232 539 632 216 517 10,789 9,574 10,562 • of which Ryzodeg ® 4,929 3,730 2,889 701 587 495 2,782 1,965 1,218 1,446 1,178 1,176 — — — — — — 4,929 3,730 2,889 • of which NovoMix ® 5,214 5,612 7,134 1,936 1,983 2,127 2,002 2,476 3,694 1,276 1,153 1,313 646 232 539 632 216 517 5,860 5,844 7,673 Fast-acting insulin 10,563 10,415 10,826 6,934 6,695 6,456 1,474 1,545 1,942 2,155 2,175 2,428 7,959 5,534 6,637 7,773 5,265 6,247 18,522 15,949 17,463 • of which Fiasp ® 1,609 1,512 1,354 1,289 1,266 1,138 — — — 320 246 216 260 661 649 213 618 606 1,869 2,173 2,003 • of which NovoRapid ® 8,954 8,903 9,472 5,645 5,429 5,318 1,474 1,545 1,942 1,835 1,929 2,212 7,699 4,873 5,988 7,560 4,647 5,641 16,653 13,776 15,460 Human insulin 5,388 6,134 6,508 1,762 1,919 1,983 806 1,213 1,812 2,820 3,002 2,713 1,579 1,460 1,678 1,535 1,406 1,605 6,967 7,594 8,186 Total insulin 38,978 37,230 38,760 19,019 18,287 18,218 9,760 8,848 10,302 10,199 10,095 10,240 16,395 10,792 14,192 15,478 9,818 13,054 55,373 48,022 52,952 Other Diabetes care 1,856 1,987 2,428 688 661 717 782 892 1,181 386 434 530 264 325 797 213 267 660 2,120 2,312 3,225 Total Diabetes care 85,806 77,834 67,384 44,266 39,673 33,790 17,790 15,948 15,220 23,750 22,213 18,374 120,812 95,632 72,164 112,386 87,768 66,881 206,618 173,466 139,548 Wegovy ® 11,425 1,913 54 7,513 1,913 54 196 — — 3,716 — — 46,781 29,430 6,134 45,770 29,430 6,134 58,206 31,343 6,188 Saxenda ® 5,563 6,402 5,832 2,920 3,780 3,561 102 146 133 2,541 2,476 2,138 1,377 3,887 4,844 777 3,306 4,368 6,940 10,289 10,676 Total Obesity care 16,988 8,315 5,886 10,433 5,693 3,615 298 146 133 6,257 2,476 2,138 48,158 33,317 10,978 46,547 32,736 10,502 65,146 41,632 16,864 Diabetes and Obesity care total 102,794 86,149 73,270 54,699 45,366 37,405 18,088 16,094 15,353 30,007 24,689 20,512 168,970 128,949 83,142 158,933 120,504 77,383 271,764 215,098 156,412 Rare disease segment: Rare blood disorders 6,442 6,432 6,671 3,924 4,021 3,795 363 372 604 2,155 2,039 2,272 5,696 5,344 5,035 5,387 5,070 4,710 12,138 11,776 11,706 • of which Haemophilia A 1,906 1,939 1,769 1,231 1,271 1,137 236 223 81 439 445 551 548 483 569 537 468 543 2,454 2,422 2,338 • of which Haemophilia B 649 584 479 436 377 294 17 13 13 196 194 172 657 477 280 486 336 152 1,306 1,061 759 • of which NovoSeven ® 3,735 3,789 4,335 2,168 2,285 2,311 110 136 510 1,457 1,368 1,514 4,248 4,169 3,973 4,135 4,065 3,811 7,983 7,958 8,308 Rare endocrine disorders 2,032 2,045 4,904 1,038 699 2,232 41 216 246 953 1,130 2,426 2,961 1,791 2,234 2,922 1,757 2,205 4,993 3,836 7,138 Other Rare disease 963 1,006 1,002 741 781 804 9 5 6 213 220 192 545 545 696 160 203 358 1,508 1,551 1,698 Rare disease total 9,437 9,483 12,577 5,703 5,501 6,831 413 593 856 3,321 3,389 4,890 9,202 7,680 7,965 8,469 7,030 7,273 18,639 17,163 20,542 Total sales by geographical area 112,231 95,632 85,847 60,402 50,867 44,236 18,501 16,687 16,209 33,328 28,078 25,402 178,172 136,629 91,107 167,402 127,534 84,656 290,403 232,261 176,954 Total sales growth as reported 17.4 % 11.4 % 16.7 % 18.7 % 15.0 % 17.3 % 10.9 % 2.9 % 1.2 % 18.7 % 10.5 % 28.2 % 30.4 % 50.0 % 35.4 % 31.3 % 50.6 % 34.4 % 25.0 % 31.3 % 25.7 % 2.3 Research and development costs DKK million 2024 2023 2022 Employee costs (note 2.4) 15,923 12,429 9,952 Amortisation, intangible assets (note 3.1) 931 649 604 Impairment losses and reversals, intangible assets (note 3.1) 7,912 1,108 760 Depreciation, property, plant and equipment (note 3.2) 1,120 1,053 898 Impairment losses, property, plant and equipment (note 3.2) 78 260 24 Clinical trial cost 12,232 9,468 6,313 Other research and development costs 9,866 7,476 5,496 Total research and development costs 48,062 32,443 24,047 As percentage of net sales 16.6% 14.0% 13.6% Novo Nordisk's research and development is mainly focused on: • Insulins, GLP-1s and other therapeutic compounds for diabetes treatment • GLP-1s, combinations and new modes of action for Obesity care • Blood-clotting factors and new modes of action for treatment of haemophilia • Novel targets within cardiovascular disease focusing on ASCVD and Heart failure • Human growth hormone and new modes of action for treatment of growth disorders and other rare endocrine disorders • New indications with existing assets within MASH, Alzheimer’s disease and • Research technology platforms including cell therapy and RNAi for treatment of MASH, cardiovascular disease, chronic kidney disease and Parkinson's disease, among others The research activities mainly utilise biotechnological methods based on advanced protein chemistry and protein engineering. These methods have played a key role in the development of the production technology used to manufacture insulin, GLP-1, recombinant blood-clotting factors and human growth hormone. Research activities further utilise digital scientific methodologies and other technology platforms including stem cells, gene therapy, small molecules and RNAi therapies. Research and development activities are mainly carried out by Novo Nordisk's research and development centres in Denmark, the US, the UK and China. Clinical trials are carried out all over the world. Novo Nordisk also enters into partnerships Other research and development costs mainly comprise external consulting ACCOUNTING POLICIES Novo Nordisk expenses all research costs. Due to significant regulatory uncertainties and other uncertainties inherent in the development of new products, internal and subcontracted development costs are also expensed as they are incurred, in line with industry practice. This means that they do not qualify for capitalisation as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. Costs for post-approval activities that are required by authorities as a condition for obtaining regulatory approval are recognised as research and development costs . Research and development costs primarily comprise employee costs as well as internal and external costs related to execution of studies, including manufacturing costs and facility costs of the research centres. The costs also comprise amortisation, depreciation and impairment losses related to intellectual property rights and property, plant and equipment used in the research and development activities. Amortisations of intellectual property rights related to marketed products are recognised in cost of goods sold. Royalty expenses paid to partners after regulatory approval are also expensed as cost of goods sold. Contractual research and development obligations to be paid in the future are disclosed separately as commitments in note 5.2. 2.4 Employee costs DKK million 2024 2023 2022 Wages and salaries 52,311 42,867 34,575 Share-based payment costs (note 5.1) 2,289 2,149 1,539 Pensions – defined contribution plans 4,235 3,267 2,472 Pensions – defined benefit plans 156 126 185 Other social security contributions 3,505 3,039 2,713 Other employee costs 4,929 4,066 3,105 Total employee costs for the year 67,425 55,514 44,589 Employee costs capitalised as intangible assets and property, plant and equipment (3,540) (2,337) (1,451) Change in employee costs capitalised (470) (409) (70) Total employee costs 63,415 52,768 43,068 Included in the income statement: Cost of goods sold 20,074 15,490 11,766 Sales and distribution costs 22,920 20,810 17,700 Research and development costs 15,923 12,429 9,952 Administrative costs 4,265 3,962 3,517 Other operating income and expenses 233 77 133 Total employee costs in the 63,415 52,768 43,068 Number of employees Number 2024 2023 2022 Average number of full-time employees 69,480 59,552 51,046 Year-end number of full-time employees 76,302 63,370 54,393 Year-end employees (total) 77,349 64,319 55,185 ACCOUNTING POLICIES Wages, salaries, social security contributions, annual leave and sick leave, bonuses 2.5 Other operating income and expenses ACCOUNTING POLICIES Other operating income and expenses, include mainly licence income and amortisations and impairment losses, which are of a secondary nature in relation to the main activities of Novo Nordisk. Operating profit from wholly owned subsidiaries, not related to Novo Nordisk's Other operating income and expenses, also includes transaction costs in fer to note 5.3 for details on the acquisition of businesses. 2.6 Income taxes and deferred income taxes Income taxes expensed DKK million 2024 2023 2022 Current tax on profit for the year 32,082 25,918 17,829 Deferred tax on profit for the year (5,484) (4,464) (3,806) Tax on profit for the year 26,598 21,454 14,023 Current tax adjustments recognised 172 (916) 339 Deferred tax adjustments recognised (567) 453 (825) Income taxes in the income statement 26,203 20,991 13,537 Tax on other comprehensive income (1,343) 359 889 Computation of effective tax rate DKK million 2024 2023 2022 Statutory corporate income tax rate in Denmark 22.0 % 22.0 % 22.0 % Deviation in foreign subsidiaries' tax rates compared to the Danish tax rate (net) (0.5%) (0.9%) (1.1%) Non-taxable income less non-tax-deductible expenses (net) (0.7%) (0.7%) (0.5%) Other adjustments (net) (0.2%) (0.3%) (0.8%) Effective tax rate 20.6 % 20.1 % 19.6 % Income taxes paid DKK million 2024 2023 2022 Income taxes paid in Denmark for 21,810 16,899 7,481 Income taxes paid outside Denmark 7,826 8,998 7,034 Income taxes paid 29,636 25,897 14,515 The deviation in foreign subsidiaries' tax rates from the Danish tax rate is mainly driven by Swiss and US business activities. Other adjustments consist of tax related From 1 January 2024 Novo Nordisk is subject to Global Minimum Tax (OECD BEPS Pillar 2 rules). The rules did not have a material impact on the tax position of Novo Nordisk in 2024. KEY ACCOUNTING ESTIMATES REGARDING DEFERRED INCOME TAX ASSETS AND PROVISIONS FOR UNCERTAIN TAX POSITIONS Management has considered future taxable income and has estimated the amount In the course of conducting business globally, tax and transfer pricing disputes with tax authorities may occur. Management has estimated the expected outcome of the disputes by using the ‘most likely outcome’ method to determine the provisions for uncertain tax positions. Management considers the provisions made to be adequate. However, the actual obligation may deviate and depends on the result of litigation ACCOUNTING POLICIES The tax expense for the period comprises current and deferred tax. It also includes adjustments to previous years and changes in provisions for uncertain tax positions. Tax is recognised in the income statement except to the extent that it relates to items recognised in equity or other comprehensive income. Provisions for ongoing tax disputes are included as part of deferred tax assets, tax receivables and tax payables. Deferred income taxes arise from temporary differences between the accounting In general, the Danish tax rules related to dividends from group companies provide exemption from tax for most repatriated profits. In some countries withholding tax will be applied to dividends paid to Denmark. A provision for withholding tax is only recognised if a concrete distribution of dividends is planned. The unrecognised potential withholding tax amounts to DKK 1,228 million (DKK 1,026 million in 2023). The value of future tax deductions in relation to share programmes is recognised Development in deferred income tax assets and liabilities Property, Intangible Inventories Liabilities Other Offset Total DKK million 2024 Net deferred tax asset/(liability) at the beginning of the year (2,561) (10,241) 1,717 14,427 6,876 — 10,218 Income/(charge) to the income statement (207) 427 2,142 3,485 204 — 6,051 Income/(charge) to other comprehensive income — (254) (71) 17 1,622 — 1,314 Income/(charge) to equity — 254 — — (314) — (60) Additions from acquisitions (2,723) 3,693 — 25 102 — 1,097 Effect of exchange rate adjustment (116) (145) 2 773 67 — 581 Net deferred tax asset/(liability) at the end of the year (5,607) (6,266) 3,790 18,727 8,557 — 19,201 Classified as follows: Deferred tax asset at the end of the year 497 225 3,847 18,989 13,112 (12,043) 24,627 Deferred tax liability at the end of the year (6,104) (6,491) (57) (262) (4,555) 12,043 (5,426) 2023 Net deferred tax asset/(liability) at the beginning of the year (2,402) (8,279) 2,595 11,007 3,922 — 6,843 Income/(charge) to the income statement (213) (2,106) (645) 3,973 3,002 — 4,011 Income/(charge) to other comprehensive income — — (224) (6) (129) — (359) Income/(charge) to equity — — — — (120) — (120) Additions from acquisitions — — — — 62 — 62 Effect of exchange rate adjustment 54 144 (9) (547) 139 — (219) Net deferred tax asset/(liability) at the end of the year (2,561) (10,241) 1,717 14,427 6,876 — 10,218 Classified as follows: Deferred tax asset at the end of the year 433 245 1,820 14,792 6,986 (3,896) 20,380 Deferred tax liability at the end of the year (2,994) (10,486) (103) (365) (110) 3,896 (10,162) |
